Adamas Pharmaceuticals had to price its IPO at the low end of the range today, then saw the stock price surge in early trading. But the lingering damage of a failed Phase IIb study could be seen when Cerulean stumbled onto the IPO stage after cutting its share price to a mere $7, well below the $11 to $13 range that had been hoped for.
With seed funding from Atlas Venture and an early-stage partnership with Roche, startup Spero Therapeutics is striking out with a novel approach to drug-resistant bacteria amid an antibiotic sea change in the industry.
Even after out-licensing a pair of hepatitis C therapeutic candidates to Vertex, which was bidding on finding a contender as a new wave of transformational drugs approached the market, South San Francisco-based Alios BioPharma stubbornly maintained a very low profile.
Deerfield Management, one of the busiest institutional players in the biotech scene, has rounded up $1.6 billion to back a new wave of biopharma companies, a major niche for this big healthcare gambler.
Cambridge, MA's Neurovance has reeled in a $6.3 million extension to its earlier Series A, money it'll use to push forward with a promising nonstimulant treatment for attention deficit hyperactivity disorder.
San Francisco biotech bankroller Foresite Capital has closed a $300 million second fund, setting out to invest in drugmakers with a clear path to market amid some renewed optimism in life sciences venture capital.
For most biotechs, the huge cost of a late-stage diabetes drug program is enough to shut down any discussion about pushing through alone to an approval. Intarcia, though, says it now has the money needed to do just that for new technology billed as a prospective game-changer for one of the world's most prevalent diseases.
As more and more drugmakers set sights on China through partnerships and acquisitions, Sino-American biotech RuiYi is taking a more direct approach, raising $15 million in venture cash to develop novel drugs in the country, for the country.
Fresh off starting up its first clinical trial, New Haven, CT's Kolltan Pharmaceuticals has wrapped up a $60 million D round, filling its coffers as it prepares for the developmental long haul with a cancer candidate.
With its $16 million Series A, Lexington, MA's scPharmaceuticals has a plan to develop a wearable drug pump and succeed where its forebear failed.